RecruitingPhase 4NCT05845489

Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- CloPidogREl for Primary preVENTION (HOST-PREVENTION)

Studying Cold agglutinin disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Seoul National University Hospital
Principal Investigator
Hyo-Soo Kim, MD, PhD
Seoul National University Hospital
Intervention
Clopidogrel treatment group(drug)
Enrollment
11086 target
Eligibility
40 years · All sexes
Timeline
20232031

Study locations (30)

Collaborators

Samjin Pharmaceutical Co., Ltd. · CKD Pharmaceutical Limited · Hanmi Pharmaceutical co., ltd. · Yuhan Pharmaceutical Company · Daewoong Pharmaceutical Co. LTD. · Dong-A ST Co., Ltd. · IlDong Pharmaceutical Co Ltd

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05845489 on ClinicalTrials.gov

Other trials for Cold agglutinin disease

Additional recruiting or active studies for the same condition.

See all trials for Cold agglutinin disease

← Back to all trials